Hidradenitis suppurativa
MONDO:0006559A chronic suppurative and cicatricial disease of the apocrine glands occurring chiefly in the axillae in women and in the groin and anal regions in men. It is characterized by poral occlusion with secondary bacterial infection, evolving into abscesses which eventually rupture. As the disease becomes chronic, ulcers appear, sinus tracts enlarge, fistulas develop, and fibrosis and scarring become evident.
Also known as: acne inversa, ectopic acne, fox den disease, hidradenitis suppurativa, pyoderma fistulans significa, verneuil disease, acne inversa, familial
132 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New hope for painful skin condition: experimental drug aims to reduce abscesses
Disease control Recruiting nowThis study tests an experimental drug called SAR445399 in 144 adults with moderate to severe hidradenitis suppurativa (HS), a painful skin condition that causes abscesses and tunnels under the skin. Participants will receive one of two doses of the drug or a placebo for 32 weeks.…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New hope for teens with painful skin condition: experimental drug povorcitinib under study
Disease control Recruiting nowThis study tests an oral drug called povorcitinib in 40 adolescents aged 12 to 17 with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition causing painful boils and tunnels. Over 54 weeks, researchers will check the drug's safety, how the body processes it,…
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
HS patients who responded to drug get extended access in new study
Disease control Recruiting nowThis study offers continued treatment with povorcitinib for up to 600 adults with hidradenitis suppurativa who completed a prior trial and saw benefit. The main goal is to track side effects over time, with a secondary focus on reducing skin abscesses, nodules, and tunnels. Parti…
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New study monitors Real-World impact of secukinumab on painful skin condition
Disease control Recruiting nowThis study follows 142 Canadian adults with moderate-to-severe hidradenitis suppurativa who are prescribed secukinumab as part of their regular care. Researchers will track changes in disease severity over 12 months using a standard scoring system. The goal is to understand how w…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New hope for teens with severe skin disease: drug trial launches
Disease control Recruiting nowThis study tests a drug called bimekizumab in teenagers (ages 9 to 17) with moderate to severe hidradenitis suppurativa, a painful skin condition that causes boils. The goal is to see how the drug moves through the body and if it is safe. About 40 participants will receive the dr…
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug brivekimig aims to tame painful skin abscesses in hidradenitis suppurativa
Disease control Recruiting nowThis Phase 2 study tests brivekimig, an injected drug, in 208 people with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition causing painful abscesses and tunnels. Participants receive different doses of brivekimig or a placebo for up to 48 weeks. The main…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New pill for painful skin disease enters first human tests
Disease control Recruiting nowThis first-in-human trial tests an oral drug called SAR447971 (KT-485) in healthy volunteers and people with hidradenitis suppurativa (HS), a chronic skin condition causing painful lumps. The study has three parts: single and multiple doses in healthy people, and multiple doses i…
Phase: PHASE1 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New shot could tame painful skin condition
Disease control Recruiting nowThis early-phase trial tests siplizumab, a drug given as a shot under the skin, in 12 adults with moderate-to-severe hidradenitis suppurativa (painful boils) that hasn't improved with standard treatments. The main goal is to see if the drug safely reduces the number of inflamed l…
Phase: EARLY_PHASE1 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New hope for painful skin condition: drug trial targets chinese patients
Disease control Recruiting nowThis study tests a drug called secukinumab in Chinese adults with moderate to severe hidradenitis suppurativa, a painful skin condition that causes boils and tunnels under the skin. The goal is to see if the drug reduces skin lesions and prevents flare-ups over 16 weeks. About 36…
Phase: PHASE4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for painful skin condition: drug trial targets stubborn HS
Disease control Recruiting nowThis study tests a new drug called BFB759 for people with moderate to severe hidradenitis suppurativa (HS), a painful skin condition that causes boils and abscesses. About 210 adults will receive either BFB759 or a placebo to see if the drug reduces the number of painful bumps an…
Phase: PHASE2, PHASE3 • Sponsor: Bluefin Biomedicine, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Could radiation ease severe armpit skin disease?
Disease control Recruiting nowThis study tests whether high-dose radiotherapy can improve symptoms of hidradenitis suppurativa, a painful skin condition. Ten adults with moderate to severe disease will receive radiation to one armpit while the other armpit gets standard care. Researchers will compare changes …
Phase: NA • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for HS sufferers: LAD191 enters Mid-Stage trial
Disease control Recruiting nowThis study tests a new injectable drug called LAD191 in 200 adults with moderate-to-severe hidradenitis suppurativa (HS), a painful skin condition causing abscesses and scarring. Participants will receive either LAD191, a placebo, or an active comparator (adalimumab) to see if LA…
Phase: PHASE2 • Sponsor: Almirall, S.A. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New hope for painful skin condition: experimental drug enters mid-stage trial
Disease control Recruiting nowThis study tests an experimental drug called SCT650C in 60 adults with moderate to severe hidradenitis suppurativa (HS), a painful skin condition causing boils and tunnels. The goal is to see if the drug can reduce abscesses and inflammation by at least 75% after 16 weeks. Partic…
Phase: PHASE2 • Sponsor: Sinocelltech Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New pill could ease painful skin lumps for those failed by antibiotics
Disease control Recruiting nowThis study tests a daily pill called ritlecitinib for adults with moderate to severe hidradenitis suppurativa (HS), a condition causing painful red skin lumps. About 240 participants who haven't been helped by antibiotics will be randomly assigned to get the drug or a placebo for…
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New cream could ease painful skin bumps for HS patients
Disease control Recruiting nowThis study tests a cream called ruxolitinib for people with mild to moderate hidradenitis suppurativa (HS), a chronic skin condition causing painful bumps and tunnels. About 550 participants will apply the cream or a placebo twice daily for several weeks. The main goal is to see …
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New cream could ease painful skin condition
Disease control Recruiting nowThis early-stage trial tests a cream called ruxolitinib on people with hidradenitis suppurativa, a condition causing painful lumps under the skin. The study includes 24 adults and teens and focuses on safety and how much of the drug gets into the body. Participants apply the crea…
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Hope for painful skin condition: new pill trial targets hidradenitis suppurativa
Disease control Recruiting nowThis study tests a daily pill called upadacitinib for people with moderate to severe hidradenitis suppurativa (HS), a painful skin condition causing boils in the armpits, groin, and genital area. The trial includes about 1,328 adults and teens who have not improved with standard …
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Cosentyx under Real-World watch for kids and adults with skin and joint disease
Disease control Recruiting nowThis study tracks the safety and effectiveness of the drug Cosentyx (secukinumab) in Korean patients with hidradenitis suppurativa, pediatric plaque psoriasis, or juvenile idiopathic arthritis. Researchers will monitor 76 participants for side effects and how well the drug works …
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New pill could ease painful skin bumps in hidradenitis suppurativa
Disease control Recruiting nowThis study tests a new drug called zasocitinib for people with moderate to severe hidradenitis suppurativa (HS), a skin condition causing painful, pus-filled bumps. About 90 adults will receive either the drug or a placebo for 4 months, then all will get the drug for 8 more month…
Phase: PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Poop pills aim to treat painful skin disease
Disease control Recruiting nowThis early study tests whether taking capsules containing donor fecal bacteria can change the gut and skin bacteria of people with hidradenitis suppurativa (HS), a painful skin condition. Sixteen adults with HS will receive either the bacteria capsules or a placebo for three week…
Phase: EARLY_PHASE1 • Sponsor: University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New IV drug NAV-240 aims to calm painful skin bumps in hidradenitis suppurativa
Disease control Recruiting nowThis study tests whether NAV-240, given as an IV infusion, works better than a placebo for adults with moderate-to-severe hidradenitis suppurativa (HS). HS causes painful, inflamed bumps and tunnels under the skin. The main goal is to see if NAV-240 can reduce these bumps by at l…
Phase: PHASE2 • Sponsor: Navigator Medicines, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New drug aims to calm painful skin flares in hidradenitis suppurativa
Disease control Recruiting nowThis early-stage trial is testing a new drug called HB0043 in 15 adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition causing painful abscesses. The drug is a bispecific antibody that targets two inflammatory proteins (IL-17A and IL-36R) to reduc…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New foam could ease painful skin condition
Disease control Recruiting nowThis study tests a medicated foam (roflumilast) applied to the skin for hidradenitis suppurativa, a painful inflammatory condition. Ten adults will use the foam alone or with their usual treatments for 4 months. Researchers will check if it improves symptoms and analyze skin gene…
Phase: PHASE2 • Sponsor: Tulane University • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Last-Resort drug access opens for severe HS patients
Disease control AVAILABLEThis program provides access to secukinumab (AIN457) for people with hidradenitis suppurativa who have no other treatment options. It is for patients with serious disease who cannot join a clinical trial or have exhausted all available therapies. Doctors must request access on be…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Botox injections could tame painful skin disease
Disease control Recruiting nowThis study is testing whether Botox injections can reduce inflammation in people with hidradenitis suppurativa (HS), a chronic skin condition that causes painful lumps. Researchers believe that blocking certain nerve signals may calm the immune response. The study will enroll 20 …
Sponsor: University of Massachusetts, Worcester • Aim: Disease control
Last updated Jun 26, 2026 17:21 UTC
-
New PET tracer aims to reveal hidden inflammation in cancer patients
Diagnosis Recruiting nowThis early-stage study tests a new imaging agent called 18F-4FN for PET scans to safely detect inflammation in the body. It involves 55 adults with cancer who are on immunotherapy or have suspected inflammation. The goal is to see if this agent can highlight areas of inflammation…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 12:36 UTC
-
AI reads your skin: new tool aims to help doctors spot rashes and moles
Diagnosis Recruiting nowThis study is testing a software tool called Belle.ai that uses artificial intelligence to help doctors diagnose common skin diseases. About 400 patients at dermatology clinics will have three photos taken of their skin condition. The AI will analyze the photos and suggest possib…
Sponsor: Wake Forest University Health Sciences • Aim: Diagnosis
Last updated Jun 27, 2026 07:55 UTC
-
New dressing aims to ease pain after HS surgery
Symptom relief Recruiting nowThis study compares a new wound dressing, Pelashield PainGuard, to the standard Restrata dressing for people with severe hidradenitis suppurativa (HS) who need surgery. The new dressing contains silver to fight bacteria and lidocaine to numb pain. Researchers will track healing t…
Phase: NA • Sponsor: Rutgers, The State University of New Jersey • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
New hope for painful skin condition: experimental drug CIT-013 enters Mid-Stage trial
Symptom relief Recruiting nowThis study tests whether a new drug called CIT-013 can reduce symptoms of hidradenitis suppurativa, a chronic skin condition causing painful lumps. About 96 adults with moderate to severe HS will receive either 50 mg, 100 mg, or a placebo every two weeks for 12 weeks. Researchers…
Phase: PHASE2 • Sponsor: Citryll BV • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
New cream could ease painful skin bumps for HS sufferers
Symptom relief Recruiting nowThis study tests a cream called ruxolitinib for people with mild to moderate hidradenitis suppurativa (HS), a condition causing painful bumps under the skin. About 550 adults with HS will use the cream or a placebo for several weeks to see if it reduces flare-ups and improves sym…
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Symptom relief
Last updated Jun 27, 2026 12:05 UTC
-
New foam could ease painful skin bumps
Symptom relief Recruiting nowThis study tests a medicated foam (roflumilast) applied to the skin for hidradenitis suppurativa, a condition causing painful bumps and abscesses. About 20 adults with mild to moderate HS will use the foam for 16 weeks. The goal is to see if it reduces the number of inflamed nodu…
Phase: PHASE2 • Sponsor: Beth Israel Deaconess Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 09:05 UTC
-
New program aims to reduce shame from chronic illness
Symptom relief Recruiting nowThis study tests a group counseling program called Healing HEARTS to help people with conditions like obesity, skin disease, cancer, HIV, diabetes, or chronic pain deal with internalized stigma. Participants will either join the counseling program or a peer support group. The goa…
Phase: NA • Sponsor: University of Florida • Aim: Symptom relief
Last updated Jun 27, 2026 09:02 UTC
-
New study tracks HS patient happiness on cosentyx
Symptom relief Recruiting nowThis study surveys 77 adults with moderate to severe hidradenitis suppurativa (HS) in Saudi Arabia who are starting the medication Cosentyx (secukinumab). Researchers will ask patients about their treatment satisfaction and quality of life after 24 weeks. The goal is to understan…
Sponsor: Novartis Pharmaceuticals • Aim: Symptom relief
Last updated Jun 27, 2026 08:07 UTC
-
Laser zaps painful lumps in early HS trial
Symptom relief Recruiting nowThis pilot study tests a 1726-nm laser (AviClear) to reduce painful lumps and abscesses in hidradenitis suppurativa (HS), a chronic skin condition. Thirty adults with mild-to-moderate HS will have one side of their body treated with the laser and the other side with a sham proced…
Phase: PHASE1 • Sponsor: Wynn Medical Center • Aim: Symptom relief
Last updated Jun 26, 2026 17:30 UTC
-
Worldwide study aims to uncover hidden patterns in hidradenitis suppurativa care
Knowledge-focused Recruiting nowThis international study observes how people with hidradenitis suppurativa (a chronic skin condition) access healthcare, what treatments they receive, and how the disease affects their quality of life. Researchers collect data from routine medical records across multiple countrie…
Sponsor: Julia Tatjana Maul • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Can a skin biopsy tell your doctor which treatment will work?
Knowledge-focused Recruiting nowThis study is collecting skin and blood samples from 830 people with chronic inflammatory skin diseases like psoriasis, eczema, and lupus. Researchers want to find biological markers that can predict how well a person will respond to treatment after one year. The goal is to move …
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:08 UTC
-
Scientists seek skin samples to unlock disease secrets
Knowledge-focused Recruiting nowThis study collects biological samples—like blood, skin biopsies, and swabs—from people with or at risk for skin diseases, as well as healthy volunteers. Researchers will use these samples to study the causes of skin conditions and explore potential treatments. Up to 700 particip…
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Italian study tracks Real-World use of secukinumab for painful skin condition
Knowledge-focused Recruiting nowThis study follows 250 Italian adults with moderate to severe hidradenitis suppurativa (a chronic skin disease causing painful lumps) who are starting secukinumab. Researchers will track how well the drug reduces skin lesions over time and how it affects healthcare use and costs.…
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Scientists launch major study to unravel mysteries of painful skin disease
Knowledge-focused Recruiting nowThis study is collecting data from 1,000 people with hidradenitis suppurativa (HS), a painful and poorly understood skin condition. Researchers aim to identify key clinical and biological features of HS to create a classification system and find potential treatment targets. Parti…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
New study checks drug levels in breast milk for nursing moms
Knowledge-focused Recruiting nowThis study looks at how much of the drug bimekizumab passes into breast milk. Researchers will collect milk samples from 20 breastfeeding mothers with conditions like psoriasis or arthritis over several weeks. The goal is to understand potential exposure for nursing infants, not …
Phase: PHASE1 • Sponsor: UCB Biopharma SRL • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Massive HS study aims to unlock secrets of debilitating skin disease
Knowledge-focused Recruiting nowThis study is creating a large registry of 3,000 people with hidradenitis suppurativa (HS), a painful and poorly understood skin condition. Researchers will collect medical information and biological samples over time to learn more about how HS progresses and what causes it. The …
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Gene-Modified cell therapy: researchers track Long-Term safety in arthritis and skin disease patients
Knowledge-focused Recruiting nowThis study monitors 36 people who previously received an experimental gene-modified regulatory T cell (Treg) therapy for rheumatoid arthritis or hidradenitis suppurativa. The goal is to check for any delayed side effects and see how long the modified cells last in the body. Parti…
Sponsor: Sonoma Biotherapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Scientists seek skin samples to unlock secrets of common rashes
Knowledge-focused Recruiting nowThis study collects skin samples from 500 people with conditions like acne, eczema, and psoriasis, as well as healthy volunteers. Researchers will analyze the samples to find biomarkers and gene patterns linked to inflammation. The goal is to better understand these skin diseases…
Sponsor: Innovaderm Research Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Scientists track prednisolone levels to improve dosing for inflammatory conditions
Knowledge-focused Recruiting nowThis pilot study is measuring prednisolone levels in 120 people with inflammatory diseases like thyroid eye disease, vasculitis, COPD, asthma, and others. Participants take high-dose prednisolone as part of their routine care, and researchers take timed blood samples to see how t…
Sponsor: Imperial College London • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Skin biobank launches to unlock secrets of inflammatory disease
Knowledge-focused Recruiting nowThis study collects skin samples and medical information from people with hidradenitis suppurativa and other skin conditions. The goal is to create a biobank that scientists can use in future studies to better understand inflammatory skin disorders. Participants are seen at Ohio …
Sponsor: Ohio State University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
When to boost? new trial seeks best COVID-19 shot timing for vulnerable patients
Knowledge-focused Recruiting nowThis study looks at 320 adults who are about to start strong immune-suppressing therapy and have already had at least two COVID-19 shots. Researchers want to find out if giving a COVID-19 booster right before starting therapy or waiting six months provides better protection. Part…
Phase: PHASE3 • Sponsor: Kirby Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
New registry tracks Real-World use of myriad™ in wound reconstruction
Knowledge-focused Recruiting nowThis observational study follows 800 adults who receive Myriad™ during soft tissue reconstruction for wounds like abdominal dehiscence, pressure injuries, or anal fistulas. Researchers track healing time, complications, and side effects to understand how well the material works i…
Sponsor: Aroa Biosurgery Limited • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC
-
Massive global study launches to measure hidden toll of skin diseases
Knowledge-focused Recruiting nowThis study aims to understand how alopecia areata, vitiligo, and hidradenitis suppurativa affect the quality of life and daily functioning of teenagers and adults. Researchers will collect information from nearly 2,800 participants across multiple countries using surveys and skin…
Sponsor: AbbVie • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
Cancer Patients' skin woes under the microscope
Knowledge-focused Recruiting nowThis study looks at how skin conditions related to cancer or cancer treatments affect the well-being of cancer patients and survivors. About 1,025 participants will fill out questionnaires about their skin condition. The goal is to better understand these effects and improve trea…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
Scientists launch major study to unravel hidrosadenitis mysteries
Knowledge-focused Recruiting nowThis study is following 465 people with hidrosadenitis (a painful skin condition) to identify different forms of the disease. Researchers hope that by understanding these variations, they can develop better, more personalized treatments. No new drugs or procedures are being teste…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:53 UTC